MA-VELSERA
12.1.2023 19:41:38 CET | Business Wire | Press release
New company Velsera was announced today at the J.P. Morgan Healthcare Conference in San Francisco, California. The vision for Velsera is supported by thematic-focused impact fund Summa Equity (“Summa”).
The promise of precision medicine is held back by barriers across routine health practice and discovery. Existing companies offer partial solutions, but no single company enables the unlocking of insights waiting to be revealed inside data - the status quo is siloed and disconnected. Velsera enables the democratization of omic data across clinical and research applications.
Velsera transforms science, technology, and informatics into an ecosystem of insight, making data actionable through the integration of a rich software platform, deep domain expertise, and knowledge that accelerate the pace and potential of multi-omics. Velsera sets out to amplify the impact of clinicians, researchers and scientists for the benefit of patients around the world.
Velsera’s initial formation comes with the acquisition of three global, industry-leading companies in the healthcare and life science industries: Pierian, Seven Bridges, and UgenTec. Velsera unites these companies to advance and bring together their missions which are centered around improving health globally through multi-omics and insights. The integrated business will remain actively engaged with existing customers, enhance current offerings, accelerate new offerings, and bring integrated solutions to market as the leading provider of global omics and insights.
-
Pierian (www.pieriandx.com) - Based in St. Louis, MO, Pierian is a global leader in clinical genomics technology and services supporting a network of laboratories around the globe. Pierian curates the world’s genetic knowledge and offers sophisticated analysis tools to allow for rapid, concise clinical reporting. Its advanced interpretation technology uses adaptive learning algorithms to connect diverse sources of information through machine learning to ensure results are comprehensive and up to date.
-
Seven Bridges (www.sevenbridges.com) - Boston, MA-based Seven Bridges enables researchers to extract meaningful insights from multi-omic, phenotypic and other high throughput data modalities. The Seven Bridges ecosystem consists of a scalable, secure multi-cloud analytic platform, petabytes of connected biomedical data and expert on-demand professional services.
- UgenTec (www.ugentec.com) - Belgian-founded (with U.S. offices) UgenTec brings sample flow intelligence to labs, assay manufacturers and instrument partners to advance modern molecular diagnostics across routine and research applications. UgenTec software and AI solutions deliver workflow automation, testing result interpretation at scale and real-time insights for the digital, connected lab. UgenTec specialties include lab automation, PCR data analysis and clinical-grade software solutions.
Velsera, headquartered in Boston, will be led by CEO Gavin Nichols. Gavin was most recently CEO of the global Medical Imaging and eClincial company Calyx, a spinout from Parexel. He has 30+ years of business experience, with 20 years in the healthcare and pharmaceutical industries. Notably, Gavin was a life science practice partner for several years at Unisys and spent over a decade at Quintiles as a Vice President, covering divisions such as Advanced Analytics, Innovation R&D, Customer Alliances and Partnerships. Nichols has also worked at Capgemini, Bioclinica, Perspectum Diagnostics, and Certara. As the Velsera CEO he will lead a diverse team of industry experts to advance precision medicine and close the value loop between clinical testing, health care and discovery of knowledge and insights for customers that improves global human health.
On leading Velsera, Nichols said: “I am very excited to launch Velsera and look forward to leading the highly accomplished teams from Pierian, Seven Bridges, and UgenTec. Our executive team has knowledge and experience that spans the ecosystem. Collectively we understand the unmet needs of customers and partners, how various stakeholders interact directly and indirectly, and how to uniquely address the unmet needs. As Velsera, we will catalyze the conversion of siloed, global data into insights from clinical and R&D settings to reveal the true promise of precision medicine. We will provide a continuous flow of knowledge among researchers, scientists and clinicians around the world to accelerate the impact of research, expand access to clinical care, and radically improve human health.”
“Summa is driven by a mission to improve the world, through our impact-focused investments in era-defining issues. We believe that the combination of these three leading healthcare and life sciences companies will accelerate innovation and deliver change at remarkable scale, contributing to the Summa thesis and our dedication to the UN Sustainable Development Goals. Velsera’s creation meets UN SDG Goal 3, good health and well-being, by reducing the cost of development of new diagnostics, therapies and drugs, as well as increasing access for underserved populations, and driving global adoption of new bio-computational methods,” comments Hans Cobben, Chair of the Board of Velsera and thematic partner at Summa Equity.
About Velsera
Velsera is the precision engine company. We connect healthcare and life sciences to reveal the true promise of precision medicine - a continuous flow of knowledge among researchers, scientists and clinicians around the world, creating insights that radically improve human health. Today Velsera comprises three global, industry leading organizations in the healthcare and life science industries: Pierian, Seven Bridges, and UgenTec, and growth and expansion should be expected in 2023 and beyond. For more information: velsera.com
About Summa Equity
Summa invests in companies that are solving global challenges and creating positive Environmental, Social, and Governance (ESG) outcomes for society.
Summa’s purpose is to co-create win-win for investors, portfolio companies, and society through aligning its vision and outcomes to the Sustainable Development Goals, ensuring a net-positive impact against ESG challenges, and the potential for long-term, sustainable outperformance.
Investments are focused on industries and companies that have tailwinds from megatrends within three sustainability themes: Resource Efficiency, Changing Demographics, and Tech-Enabled Transformation. Across these themes, Summa’s portfolio companies are supporting a world in transition and showing that business can be part of the solution. Summa Equity has c. EUR 4 billion assets under management. For more information: www.summaequity.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230112005016/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Future Health Launches Academy to Translate Life Sciences Advances Into Strategic Action18.11.2026 15:37:00 CET | Press release
Future Health Academy will build knowledge and connect expertise among health and life sciences professionals in Abu Dhabi and internationally. The Academy will support two-way knowledge exchange, bringing global expertise to Abu Dhabi while creating opportunities to share Abu Dhabi’s knowledge, expertise and innovation with the world. Inaugural course brought together senior leaders from government, healthcare, research, and industry with local and international scientific experts. Future Health - A Global Initiative by Abu Dhabi has launched the Future Health Academy as part of its year-round programme, designed to build knowledge, connect expertise and create opportunities for collaboration among health and life sciences professionals in Abu Dhabi and internationally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118051527/en/ The Future Health Academy will build knowledge and connect expertise among health and life s
Soracom Launches Physical AI Suite, Bringing Secure Connectivity and Remote Operations to Robots and Autonomous Machines18.11.2026 15:30:00 CET | Press release
Soracom suite combines existing platform services for physical AI, available worldwide Soracom, Inc. (TSE: 147A), a cloud-native IoT platform providing connectivity, cloud integration, and AI services for the Internet of Things, today announced Soracom Physical AI Suite, a set of Soracom platform services combined to connect, protect, and manage physical AI systems such as robots, autonomous mobile machines, and industrial equipment. Soracom Physical AI Suite is the company's second suite, following Soracom Automotive Suite announced in July 2026. Each suite brings together Soracom platform services commonly used for a particular type of deployment, organizing them into a single system. A team starting a new deployment begins from that system instead of selecting and assembling services one at a time. The suite is designed for companies that develop or deploy robots and other physical AI systems and for companies that operate connected equipment in industries including manufacturing, l
Variational Raises $110M Series B at $1.5B Valuation To Scale On-Chain Access To Global Markets18.11.2026 15:23:00 CET | Press release
The raise follows the rapid growth of swaps, Variational’s new instrument bringing liquidity from traditional finance on-chain. Variational, a protocol for on-chain derivatives trading, has announced a $110M Series B raise at a $1.5B valuation led by Bain Capital Crypto with support from Dragonfly, HSG, Peak XV, 50T Funds, and more. Since launching in early 2025, the platform has processed $475B+ in trading volume and accumulated $1.3B+ in open interest across 100k+ accounts. More than half of daily volume on the platform is now on traditional markets. The raise will fund the platform’s continued growth, allowing Variational to list hundreds more markets and lift open interest caps that traders increasingly hit. Omni, a trading platform built on Variational, offers leveraged trading on 550+ crypto and traditional markets. Unlike other on-chain trading platforms, Omni aggregates liquidity from both traditional and on-chain markets. This model allowed the platform to launch “swaps” in Se
Xsolla Connects Players, Brands, and Video Game Audiences Through Rewarded Engagement18.11.2026 15:00:00 CET | Press release
Players Can Choose Their Quests, Developers Get Measurable Results From Their Games, and Advertisers Get Verified Insight From Players Who Choose to Share Xsolla (USA), Inc., a global commerce company, announces Xsolla Ads, a rewarded marketing solution connecting brands with game audiences through quests players choose to take part in. Studios generate revenue beyond player purchases while brands drive measurable engagement, acquisition, and purchases. Players choose which campaigns to participate in and which rewards to receive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117947414/en/ Graphic: Xsolla Players see Xsolla Ads where they already are, including the Xsolla App, game web shops, branded pages on Xsolla, Xsolla Choice surveys, and an opt-in Offerwall. Quests are triggered by game events, such as reaching a new level or season, so studios connect campaigns to what players already do in their games. Completed
Sila Inks Long-Term Offtake Deal with Panasonic Energy to Power Domestic Battery Production18.11.2026 15:00:00 CET | Press release
Agreement to deliver Sila’s Titan Silicon® Si/C anode to Panasonic’s U.S. manufacturing sites, fortifying domestic battery supply chain resilience and advanced technology capabilities. Sila, a leading battery technology and materials company, today announced a commercial offtake agreement with Panasonic Energy Corporation of North America. The multi-year agreement is part of a long-term commercial relationship with the potential for over $1 billion of offtake over time. Sila will supply its proprietary Titan Silicon® silicon-carbon (Si/C) anode material from its Moses Lake, Washington plant to power Panasonic battery cells. The partnership is also expected to support significant manufacturing and construction job creation in the United States. With Sila’s U.S.-based anode production underpinned by proprietary American technology and know-how, Panasonic and its OEM customers gain a clearer path toward a more secure, resilient, and sustainable domestic supply chain. This press release fe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
